Health Care [ 9/12 ] | Biotechnology [ 43/73 ]
NASDAQ | Common Stock
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology.
The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015.
Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 25 | 0.01 Increased by +109.09% | -0.04 Increased by +125.00% |
| Apr 30, 25 | -0.18 Decreased by -81.60% | -0.15 Decreased by -18.08% |
| Feb 26, 25 | -0.10 Increased by +16.75% | -0.12 Increased by +14.47% |
| Nov 6, 24 | -0.09 Increased by +25.00% | -0.09 |
| Aug 1, 24 | -0.11 Decreased by -10.00% | -0.10 Decreased by -10.00% |
| May 2, 24 | -0.10 Increased by 0.00% | -0.11 Increased by +9.09% |
| Feb 29, 24 | -0.12 Increased by +14.29% | -0.12 |
| Nov 7, 23 | -0.12 Increased by 0.00% | -0.11 Decreased by -9.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 10.74 M Increased by +522.19% | 2.52 M Increased by +112.74% | Increased by +23.49% Increased by +102.05% |
| Mar 31, 25 | 1.76 M Increased by +15.14% | -24.53 M Decreased by -37.21% | Decreased by -1.39 K% Decreased by -19.16% |
| Dec 31, 24 | 1.57 M Decreased by -26.62% | -12.53 M Increased by +35.11% | Decreased by -796.19% Increased by +11.57% |
| Sep 30, 24 | 1.34 M Decreased by -71.25% | -19.72 M Increased by +1.92% | Decreased by -1.47 K% Decreased by -241.18% |
| Jun 30, 24 | 1.73 M Decreased by -62.89% | -19.80 M Decreased by -15.81% | Decreased by -1.15 K% Decreased by -212.06% |
| Mar 31, 24 | 1.53 M Decreased by -77.09% | -17.88 M Decreased by -15.60% | Decreased by -1.17 K% Decreased by -404.57% |
| Dec 31, 23 | 2.15 M Decreased by -65.65% | -19.31 M Increased by +15.71% | Decreased by -900.33% Decreased by -145.41% |
| Sep 30, 23 | 4.66 M Decreased by -21.74% | -20.10 M Decreased by -16.05% | Decreased by -431.60% Decreased by -48.29% |